MEDICAL EDUCATION GRANTS

At Travere Therapeutics, we are committed to supporting independent educational activities that increase understanding of how to improve the care of patients with rare disease

Travere may support medical education grant applications for independent education designed to close knowledge gaps identified in the healthcare landscape, drive measurable improvements in knowledge and performance of healthcare professionals, and advance patient health outcomes.

“Independent” means that the projects funded by the companies are the full responsibility of the recipient organization. Travere does not have influence over any aspect of the supported projects and only ask for interim and final outcomes reports including a description of the impact of the projects. The program must be of high quality, unbiased, innovative, and evidence based.

Travere may provide medical education grants to support independent programs for healthcare professionals, patients, consumers, and healthcare associations, foundations and institutions, in which the programs relate to our therapies or therapeutic focus areas.

 

Educational providers and the activities they develop must be compliant with all applicable laws, regulations, industry guidelines, and the ethical standards under which Travere conducts business. Medical education grant applications are reviewed for adherence to, and provided in compliance with: the ACCME Standards for Commercial Support, FDA guidance, including the FDA Guidance on Industry-Supported Scientific and Educational Activities, the AMA Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Continuing Medical Education, the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and the PhRMA Code on Interactions with HealthCare Professionals.

Our medical education grant areas of interest in IgAN

Educate healthcare professionals to create awareness of:

  1. The importance of lowering proteinuria, to preferably < 0.3 g/d, to slow disease progression and preserve kidney function for patients with IgA nephropathy (IgAN).
  2. The critical roles of endothelin-1 and angiotensin II in glomerular injury and how dual and continuous antagonism at these drug targets in a single molecule, with a DEARA, confers safety and efficacy.
  3. The critical role of nephroprotective foundational therapy in IgAN:
    • The need for kidney targeted therapy with sustained proteinuria reduction that slows the rate of kidney decline over time.
    • The safe and effective use of DEARA, a unique dual-acting molecule, as foundational therapy alone or in combination with other agents.

Our medical education grant areas of interest in FSGS

Educate healthcare professionals to create awareness of:

  1. The high unmet need in focal segmental glomerulosclerosis (FSGS) and ensure that nephrologists understand the importance of proteinuria reduction as a driver for clinical outcomes.
  2. The critical roles of endothelin-1 and angiotensin II in podocyte injury and progression to kidney failure in FSGS and the importance of dual and continuous antagonism at these drug targets.
  3. The critical role of nephroprotective foundational therapy in FSGS:
    • The need for kidney targeted therapy with sustained proteinuria reduction that reduces the risk of kidney failure.

Travere Therapeutics may support the following types of medical educational grants:

  • Medical educational grants can be certified educational programs (CME/CE)
  • Activities for non-accredited education of healthcare professionals or patients, and strictly for educational purposes

 

Grants Portal

Any personal data you provide Travere Therapeutics will be processed according to our Privacy Policies.